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patient-centered treatment assessments and growth in risk sharing assessments
will further increase the need for real-world PRO data.
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OBJECTIVES: Scales measuring perceptions of pain can include numeric rating
scales (NRS), visual analogue scales (VAS) and descriptor scales using words (ad-
jectival). With the increased use of electronic data capture in clinical trial settings,
such scales have been migrated to numerous platforms. After conducting a brief
literature review, there was found to be a lack of research on the impact that
migration of such pain scales can have on the efficacy of the scales. The objective
of this study was to deploy three pain scales in different formats and on different
platforms, and to explore preferences and perceived differences in patients who
experience daily pain. METHODS: Twelve participants diagnosed with a range of
conditions resulting in pain were interviewed in a qualitative interview setting. All
participants completed three pain scales in different formats: NRS (11-, 9-, and
7-points; portrait/ landscape), VAS (horizontally/ vertically; portrait/ landscape)
and adjectival scale (increasing/ decreasing severity). All scales were presented in
three modes of administration: paper, handheld device and tablet device. Partici-
pants were asked about perceived differences and their preferences of the different
scales, formats, and modes of administration. RESULTS: The NRS and adjectival
scale were preferred equally (n5). Participants expressed an almost unanimous
preference for the 11-point NRS and increasing severity adjectival scale, across all
administration modes. In contrast, the VAS was the least preferred scale (n7) due
to difficulty with interpretation. Participants expressed no usability problems with
the tablet or handheld devices, but the tablet was preferred overall because of the
bigger screen. CONCLUSIONS: Although the sample size makes generalising these
findings difficult, this exploratory study suggests that the preferred pain scales
may provide higher quality data as they are easier to interpret, and therefore mi-
nimise error and patient burden. Further evidence, particularly quantitative, is
required to support these preliminary findings.
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OBJECTIVES: Effective translation and adaptation of neuropsychological assess-
ments is paramount to the successful collection of data in a global context. The
structure and content of neuropsychological assessments requires specific pro-
cesses for translation and adaptation to ensure appropriate understanding in each
target language. Word list adaptation requires particular consideration, as various
criteria must be met within and between wordlists – including but not limited to
frequency, familiarity and cultural relevance to the target population, number of
syllables, and avoidance of homonyms and repeated words. This review highlights
important considerations for creation of target language word lists, and solutions
for determining appropriate adaptation methodologies. METHODS: A review of
previous translations of neuropsychological assessments, such as the ADAS, FC-
SRT, RBANS, MoCA, and MMSE, was performed. A review of translation procedures,
developer involvement, guidelines for adaptation, translation methodology, lin-
guistic decisions, and word list creation was conducted. RESULTS: Key solutions to
ensure successful adaptation of wordlists include: 1) Outline all criteria used to
develop the English word lists and assessment, 2) Create clear guidelines for adap-
tation of word lists in collaboration with the developer, if guidelines are not already
available, 3) Employ a specialized project team of project managers, native-speak-
ing medical linguists, and native-speaking neuropsychologists possessing exten-
sive expertise in the relevant neuropsychological assessments. 4) Depending upon
the assessment and the context of use, additional testing of the word lists with
local populations to ensure comprehension may be warranted. CONCLUSIONS:
Neuropsychological assessments and word lists require specialized translation
and adaptation methodologies to ensure appropriate comprehension by the target
population. Developer involvement in the creation of adaptation guidelines, and
neuropsychologist involvement in the adaptation process are critical to ensuring
adaptation is conducted appropriately. Further research is required to outline clear
guidelines for situations requiring additional testing of the word lists with local
populations to ensure comprehension.
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OBJECTIVES:Mapping or cross-walking is an accepted methodology for calculating
utilities. Different models have been proposed for mapping from disease-specific
quality-of-life (QOL) measures to generic QOL measures. Much of this work has
been done using data from rheumatoid arthritis cohorts and using measures spe-
cific to RA. The objectives of this study are to test various statistical models to
determine which provides the best fit for a psoriatic arthritis (PsA) cohort using
both newly developed composite disease measures and established measures. The
study also aimed to determine whether the composite disease measures provide a
better estimate of utility over other measures and which components of the com-
posite measures influence the relationship with QOL. METHODS: The data was
made available from the Group for Research and Assessment of Psoriasis and Pso-
riatic Arthritis (GRAPPA) which collected data from an international cohort of PsA
patients. Different regression models were used to estimate the relationship be-
tween the generic QOL measure, SF-6D and disease specific measures (HAQ,Com-
posite Disease Activity Index (CPDAI), Psoriatic ArthritiS Disease Activity Score
(PASDAS) and the Arithmetic Mean Desirability Function Score (AMDF). Model fit
was determined using the R2 statistic, root mean square error, Akaike information
criterion; regression coefficients are also presented. RESULTS: The optimal model
for each of the disease specific measures and SF-6D was a multiple regression
model. The difference in model fit between the linear and multiple regression
models was greatest for the composite disease measures specific to PsA. The CPDAI
and AMDF provided the best fit to utility score followed by the PASDAS.
CONCLUSIONS: PsA is a heterogeneous disease for which composite disease mea-
sures may be more appropriate than measures such as the HAQ. This study pro-
vides mapping coefficients, allowing utility estimation from these measures which
may be collected in trials where no preference-based utility measure has been
used.
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OBJECTIVES: To highlight some of the common areas that require particular atten-
tion when preparing clinical outcome assessment (COA) dossiers, suitable for FDA
regulatory label claims, with a particular focus on clinician-reported outcome
(ClinRO) measures. The FDA has provided guidance for the use of Patient-Reported
Outcome (PRO) measures for relevant endpoints in clinical trials to support label
claims (FDA, 2009). Although several authors have indicated that the standards
used to evaluate PRO’s will apply to all COA’s (Burke, 2011; Gwaltney, 2012), the FDA
have not published guidelines on ClinRO measures to support label claims. This is
surprising given that the ratio of label claims based on ClinRO’s is approximately
three ClinRO’s to every PRO measure (Burke, 2010). METHODS: We conducted a
review of the literature to ascertain the general level of use of ClinRO’s and to find
examples of widely used ClinRO’s. The available evidence for these ClinRO’s was
then assessed by the standards of the PRO guidance, specifically in relation to
content and construct validity, reliability and other psychometric properties.
RESULTS: The literature review revealed that ClinRO’s are common endpoints in
clinical trials. However, it was also apparent from the sample of ClinRO’s reviewed,
that they fail to meet the evaluative standards prescribed by the FDA particularly in
being “well defined and reliable”. CONCLUSIONS: ClinRO’s used as endpoints in
clinical trials to support FDA label claims may lack the required evidence set out in
the FDA PRO guidance document. Specifically, many ClinRO’s have been developed
by clinicians, and widely accepted by clinical peers, without undergoing psycho-
metric evaluation. If the FDA were to evaluate ClinRO’s to the same standards as
PRO’s, the ratio of label claims between ClinRO’s and PROs may decrease signifi-
cantly.
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OBJECTIVES: Osteoarthritis (OA) also known as degenerative arthritis or degener-
ative joint disease, is a group of mechanical abnormalities involving degradation of
joints. The daily-life of OA patient is considerably disturbed. The burden’s concept
assesses the individual burden, measuring the patient’s disability generated by the
disease in a broad sense.The aim of our study was to explore, using a question-
naire, how the burden of the OA affected a daily life, with the objective to better
anticipate difficulties and thus provide better care METHODS: The development of
the questionnaire we propose here was inspired by the construction of general
QoL- questionnaires. Two steps are required for the development:, the creation in
three stages following a strict methodological process involving a multidisciplinary
team (doctors, social workers) and patients with OA who were interviewed; Sec-
ondly, the validation of the questionnaire by testing its reliability, its construct
validity and its reproducibility. A cognitive debriefing was conducted to ensure its
reproducibility. RESULTS: A population of 198 patients with OA was enrolled to
answer to the questionnaire,( with SF12 and PGWI). We obtain a questionnaire
called “Burden-Osteoartritis-New-Scale-BONeS”. Exploratory assessments real-
ized with a population showed that the concept of burden could be structured
around 5 components: autonomy, daily life, family and personal relationships,
work and psychological impact. 41 preliminary items were identified at the end of
the verbatim. A final analysis managed to reduce to 28 items and a cognitive de-
briefing allowed to ensure its reproducibility. CONCLUSIONS: Chronic pathologies
such as OA which remains a rare and incapacitating illness are difficult to assess by
clinical or QoL aspects alone as their impact can be multidimensional. “BONeS”
takes them all into consideration in order to explain every angle of the handicap
generated. Our next objective is to develop the “BONeS” in German, Italian and
Spanish with a cross cultural validation.
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